Study of Cryoablation Combined With Cadonilimab and Bevacizumab for Liver Cancer with Lung Metastases

What this Trial Is About

Researchers are evaluating the safety and effectiveness of combining cryoablation with Cadonilimab and Bevacizumab in treating people with hepatocellular carcinoma HCC that has spread to the lungs. HCC commonly metastasizes to the lungs, and while standard treatments focus on systemic therapy, this study explores adding cryoablation, which freezes tumors to kill cancer cells and stimulate immune responses, potentially enhancing treatment outcomes. Cadonilimab is a bispecific antibody targeting immune checkpoints, and Bevacizumab targets blood vessel growth factors that may suppress immune attack on tumors. Participants receive one of two treatment plans either Bevacizumab plus Cadonilimab intravenously every three weeks, or cryoablation of lung metastases combined with the same drug regimen. Cryoablation aims to destroy lung tumors directly while the drugs work systemically to control cancer. The study is randomized and open-label, comparing these approaches to evaluate response rates and survival. During the study, participants will be monitored for tumor response, progression-free survival at six months, and overall survival at 12 months. Evaluations include imaging scans and clinical assessments to measure tumor size and treatment effects. The study duration extends up to January 2027, with regular visits for drug administration and follow-up to assess safety and efficacy outcomes.

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases